Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Pharmaceutical giant Sanofi Healthcare has leased 2.7 lakh sq ft in Hyderabad's Hitech City for over ₹2 crore monthly for a ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend ...

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Looking into the current session, Sanofi Inc. SNY shares are trading at $49.35, after a 0.24% increase. Moreover, over the ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...